Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00406900

Enrollment

560

Registered

2006-12-04

Start date

1999-01-31

Completion date

2006-09-30

Last updated

2006-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melanoma, Metastatic Disease, Radiotherapy

Keywords

uveal melanoma, metastatic disease

Brief summary

Uveal Melanoma is the most common primary intraocular tumor in adults. Most tumors metastasize to the liver. So far no sensitive or specific serological tumor marker is routinely used. The marker Melanoma inhibitory activity is a promising marker. Study hypothesis is to detect metastatic lesions in an early stage. This would increase life expectance of our patients

Detailed description

Serum is taken from each melanoma patient at every follow up after signed concent. With ELISA the marker MIA is evaluated. An increase of MIA serum level will lead to search for metastasis by oncologists.

Interventions

PROCEDURETreatment of metastatic disease

Study design

Observational model

DEFINED_POPULATION

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* uveal melanoma (With/without overt metastatic disease)

Countries

Germany

Contacts

Primary ContactUlrich C Schaller, MD

ulrich.schaller@med.uni-muenchen.de+49/89/5160

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026